Concepedia

Kirk Nelson

KN

18

Publications

1.5K

Citations

18

H-Index

2006

Active since

Affiliations

Mapp Biopharmaceutical (United States)(Current)

Arcturus Therapeutics (United States)

Molsoft (United States)

Doctors Company (United States)

Advanced Light Source

Kirk Nelson is an author at Mapp Biopharmaceutical (United States) specializing in drug discovery, drug resistance, and medicine.

ORCID

Top concepts

Publications per year

2006–2024

18

Publications

18

Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae

Olga Lomovskaya, Dongxu Sun, Debora Rubio-Aparicio et al. · Antimicrobial Agents and Chemotherapy · 2017 · 337 citations · Full text

Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases

Scott J. Hecker, K. Raja Reddy, Olga Lomovskaya et al. · Journal of Medicinal Chemistry · 2020 · 200 citations · Full text

Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity

Kirk Nelson, Peera Hemarajata, Dongxu Sun et al. · Antimicrobial Agents and Chemotherapy · 2017 · 174 citations · Full text

Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae

Dongxu Sun, Debora Rubio-Aparicio, Kirk Nelson et al. · Antimicrobial Agents and Chemotherapy · 2017 · 164 citations · Full text

Tricyclic GyrB/ParE (TriBE) Inhibitors: A New Class of Broad-Spectrum Dual-Targeting Antibacterial Agents

Leslie W. Tari, Xiaoming Li, Michael Trzoss et al. · PLoS ONE · 2013 · 103 citations · Full text

, , +17

Rows per page

1–5 of 18